Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Obudanersen sodium by Ionis Pharmaceuticals for Angelman Syndrome: Likelihood of Approval
Obudanersen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase II for Angelman Syndrome. According to GlobalData,...